Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity - Related Studies

Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP)

This study is currently recruiting participants.

Study NCT00622726. Last updated on November 14, 2008. Information provided by The University of Texas Health Science Center, Houston

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Retinopathy of Prematurity

2	Additional conditions recognized in this trial
		Retinal Diseases

3	More general conditions related to this trial
		Eye Diseases
		Infant, Newborn, Diseases
		Infant, Premature, Diseases

4	Interventions listed in this trial
		Bevacizumab
		Conventional Laser for ROP

5	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Antineoplastic Agents
		Growth Inhibitors
		Growth Substances
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		The University of Texas Health Science Center, Houston